DDP 4 inhibitors have been shown to be safe in patients with cardiac disease, but have not been shown to reduce MI, stroke or cardiac death
Clinical trials for type 2 diabetes have explored a number of agents for reducing cardiac risk, Professor Merin Thomas, a diabetologist from Monash University, says.
Due to the failure of previous medications to demonstrate cardiac safety in patients with type 2 diabetes, new medications for glucose lowering have to go through intensive study to show that the agents were safe in patients with cardiac disease.
New drugs for type 2 diabetes, such as DDP 4 inhibitors, have been shown to be safe in patients with cardiac disease, but have not been shown to reduce MI, stroke or cardiac death.
However, the studies are only a few years in length, and some cardiac benefit may be seen if patients take the medications for a decade or more, says Professor Thomas.
Click here view the full interview.
